Target intelligence / Profile preview

Dynein axonemal heavy chain 8 (DNAH8)

Target
DNAH8
Molecular classification
Motor protein, Axonemal dynein, ATPase (AAA+ ATPase family), Microtubule motor complex
01

Overview

Dynein axonemal heavy chain 8 (DNAH8) is a large motor protein component of the dynein motor complex, predominantly expressed in sperm and ciliary cells. It is critical for generating force that drives the movement of eukaryotic cilia and flagella via ATP hydrolysis and microtubule binding. DNAH8 contains conserved AAA+ ATPase domains, microtubule-binding regions, and is structurally related to other axonemal dyneins. Mutations or deficiencies in DNAH8 disrupt ciliary beating and sperm motility, resulting in diseases including primary ciliary dyskinesia, male infertility, and other ciliopathies. Recent evidence implicates DNAH8 as a regulator of androgen receptor activity, with high expression in prostate cancers associated with tumor metastasis, recurrence, and poor patient prognosis. DNAH8 is also essential for flagellar assembly and interacts with other dynein proteins such as DNAH17. There are currently no specific drugs targeting DNAH8, but experimental knockdown impacts cell proliferation in cancer models.

Other names
DNAH8Dynein axonemal heavy chain 8Axonemal beta dynein heavy chain 8Ciliary dynein heavy chain 8ATPaseSPGF46HDHC9Dynein, axonemal, heavy polypeptide 8
02

Mechanism of action

Experimental: siRNA-mediated knockdown reduces AR-dependent transcription and prostate cancer cell proliferation.

03

Biological functions

Sperm motilityCiliary and flagellar movementMicrotubule-based movementATP hydrolysisRegulation of androgen receptor (AR) transcriptional activityAssembly and stabilization of the sperm flagellum
04

Disease associations

Primary ciliary dyskinesiaSpermatogenic failure (male infertility)Kartagener syndromeSitus inversusBronchiectasisChronic sinusitisRespiratory distress syndromeCancer (notably prostate cancer: regulator of androgen receptor activity, linked with poor prognosis and metastasis)
05

Safety considerations

Targeting DNAH8 may impact ciliary and flagellar motility, potentially leading to infertility, respiratory dysfunction, or ciliary dyskinesiaTherapeutic challenges relate to its essential roles in development/reproduction and lack of specific inhibitors
06

Interacting drugs

None currently approved or directly targeting DNAH8; not a characterized direct small-molecule or biologic target, though experimental inhibition via RNAi has been used in prostate cancer studies
07

Biomarkers

DNAH8 mRNA/protein expression is associated with metastatic prostate cancer and poor prognosisDNAH8 gene amplification in metastatic tumors

Beyond the preview

Go deeper on Dynein axonemal heavy chain 8 (DNAH8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynein axonemal heavy chain 8 (DNAH8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call